TScan Therapeutics (TCRX) Net Income Growth (3y) (2023 - 2026)

TScan Therapeutics (TCRX) Net Income Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 9.16%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 38.43%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 13.80%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -3.84%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 79.26%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 TScan Therapeutics 100.59 Mn -27.47 Mn - -8.31%

Historic Data

Download Data
DateValue
Mar 31, 2026 -8.31%
Dec 31, 2025 -18.09%
Sep 30, 2025 -30.02%
Jun 30, 2025 -34.77%
Mar 31, 2025 -31.79%
Dec 31, 2024 -42.00%
Sep 30, 2024 -5.72%
Jun 30, 2024 1.28%
Mar 31, 2024 -56.18%
Dec 31, 2023 -29.58%
Sep 30, 2023 -47.47%
Jun 30, 2023 -62.41%